Pfizer Inc. (NYSE:PFE) Shares Sold by Sfmg LLC

Sfmg LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 15.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,090 shares of the biopharmaceutical company’s stock after selling 2,018 shares during the quarter. Sfmg LLC’s holdings in Pfizer were worth $319,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PFE. Adage Capital Partners GP L.L.C. grew its position in shares of Pfizer by 40.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new stake in shares of Pfizer in the 4th quarter worth $255,000. Brookstone Capital Management lifted its stake in shares of Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after acquiring an additional 212,369 shares during the period. ETF Store Inc. lifted its stake in shares of Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the period. Finally, Farmers Trust Co. lifted its stake in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after acquiring an additional 4,410 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $36.88.

Pfizer Stock Performance

Shares of PFE opened at $25.41 on Thursday. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $143.86 billion, a P/E ratio of 70.57, a PEG ratio of 1.16 and a beta of 0.61. The company has a 50-day moving average of $27.19 and a two-hundred day moving average of $28.76. Pfizer Inc. has a 12-month low of $25.26 and a 12-month high of $41.33.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.